These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37771976)

  • 1. Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population.
    Foo VHX; Liu YC; Tho B; Tong L
    Front Med (Lausanne); 2023; 10():1209886. PubMed ID: 37771976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the efficacy of Quantum Molecular Resonance (QMR) electrotherapy in mixed-type dry eye patients.
    Trivli A; Karmiris E; Dalianis G; Ruggeri A; Terzidou C
    J Optom; 2023; 16(2):128-134. PubMed ID: 35851496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye: A Randomized Interventional Study.
    Ballesteros-Sánchez A; Sánchez-González JM; Tedesco GR; Rocha-De-Lossada C; Russo F; Spinelli A; Ingrande I; Borroni D
    Ophthalmol Ther; 2024 Feb; 13(2):495-507. PubMed ID: 38113022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.
    Wang TJ; Wang IJ; Ho JD; Chou HC; Lin SY; Huang MC
    Clin Ther; 2010 Jan; 32(1):44-52. PubMed ID: 20171410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.
    Baratta RO; Schlumpf E; Del Buono BJ; DeLorey S; Ousler G; Calkins DJ
    Ophthalmol Sci; 2024; 4(3):100451. PubMed ID: 38317866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
    Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
    Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Corneal Subbasal Nerves after Punctal Occlusion in Dry Eye Disease.
    Latifi G; Banafshe Afshan A; Houshang Beheshtnejad A; Zarei-Ghanavati M; Mohammadi N; Ghaffari R; Ghassemi H; Mohammadi SS; Kheirkhah A
    Curr Eye Res; 2021 Jun; 46(6):777-783. PubMed ID: 33092431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-related differences and hormonal effects in the Dry Eye Assessment and Management (DREAM) study.
    Zhao M; Yu Y; Roy NS; Ying GS; Asbell P; Bunya VY
    Br J Ophthalmol; 2023 Dec; 108(1):23-29. PubMed ID: 36575626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial.
    Gioia N; Gerson J; Ryan R; Barbour K; Poteet J; Jennings B; Sharp M; Lowery R; Wilson J; Morde A; Rai D; Padigaru M; Periman LM
    Front Ophthalmol (Lausanne); 2024; 4():1362113. PubMed ID: 38984118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry Eye Disease in Patients with Functioning Filtering Blebs after Trabeculectomy.
    Ji H; Zhu Y; Zhang Y; Li Z; Ge J; Zhuo Y
    PLoS One; 2016; 11(3):e0152696. PubMed ID: 27032098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantum Molecular Resonance Electrical Stimulation as a Beneficial and Safe Treatment for Multifactorial Dry Eye Disease.
    Kavroulaki D; Konstantinidou E; Tsiogka A; Rallis K; Mavrikakis E
    Cureus; 2023 May; 15(5):e39695. PubMed ID: 37398748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous serum eye drops for dry eye.
    Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tear Film Osmolarity Measurement in Japanese Dry Eye Patients Using a Handheld Osmolarity System.
    Shimazaki J; Sakata M; Den S; Iwasaki M; Toda I
    Diagnostics (Basel); 2020 Oct; 10(10):. PubMed ID: 33028019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated Tear Fluid Nociception-Associated Factors, Corneal Dendritic Cell Density, and Vitamin D Levels in Evaporative Dry Eye.
    Khamar P; Nair AP; Shetty R; Vaidya T; Subramani M; Ponnalagu M; Dhamodaran K; D'souza S; Ghosh A; Pahuja N; Deshmukh R; Ahuja P; Sainani K; Nuijts RMMA; Das D; Ghosh A; Sethu S
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2532-2542. PubMed ID: 31195410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.